Urological cancers are among the most common malignancies around the world. In
particular, bladder cancer severely threatens human health due to its aggressive and …

Clinically, different approaches are adopted worldwide for the treatment of cancer, which still
ranks second among all causes of death. Immunotherapy for cancer treatment has been the …

In this study, we developed novel hyaluronic acid cross-linked zein nanogels (HA-Zein NGs)
to deliver the potential anticancer agent curcumin (CRC), a naturally occurring …

Bladder cancer (BC) is a common malignancy in the genitourinary system and the current
theranostic approaches are unsatisfactory. Sensitivity and specificity of current diagnosis …

Immunotherapy is a promising strategy to inhibit cancer progression via activation of the
immune system. In immunotherapy, adjuvants as immunologic stimulants or delivery …

Bladder cancer is one of most common malignant urinary tract tumor types with high
incidence worldwide. In general, transurethral resection of non-muscle-invasive bladder …

Bladder cancer (BCa) is one of the most prevalent cancers worldwide. The effectiveness of
intravesical therapy for bladder cancer, however, is limited due to the short dwell time and …

Erlotinib (ERL), a tyrosine kinase inhibitor approved for therapeutic use in non-small cell
lung cancer is further researched for eventual liver cancer treatment. However, conventional …

Bladder cancer (BC) is the most frequently occurring cancer of the urinary system, with non-
muscle-invasive bladder cancer (NMIBC) accounting for 75–85% of all the bladder cancers …

The blood–urine barrier is the tightest and most impermeable barrier in the body and as
such represents a problem for intravesical drug delivery applications. Differentiation …